Analyst consensus rating
Inhibikase Therapeutics Analyst Rating: none
Direct answer
Inhibikase Therapeutics's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked September 6, 2026.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.50
- Average price target
- $6.00
- High price target
- $8.00
- Low price target
- $3.00
- Low target gap
- +20%
- Target upside
- +140%
- High target gap
- +220%
- Target range width
- 200%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- September 6, 2026
- Valid through
- September 13, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Inhibikase Therapeutics?
Inhibikase Therapeutics has a verified none consensus. The same dataset has an average price target of $6.00.
How far are Inhibikase Therapeutics's low and high targets from the recorded price?
The low target implies +20%, while the high target implies +220%.
How many analysts are included in Inhibikase Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Inhibikase Therapeutics's target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $2.50, then one is subtracted to produce +140%. This does not guarantee a future return.
When was Inhibikase Therapeutics's analyst forecast verified?
The data was verified on 2026-09-06. The dataset is valid through 2026-09-13.